Internal Medicine, Pulmonary Disease · Apple Valley, CA
NPI
1679685796
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
16017 Tuscola Rd Ste A
Apple Valley, CA, 92307
Phone (760) 242-2221
Groups this clinician bills Medicare through
Medicare paid, 2024
$155K
1,223 services
Medicare patients, 2024
450
Average age 70
Drug cost, 2024
$1.7M
2,544 prescriptions
Company payments, 2025
$843
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rajeev Yelamanchili was code 99214 (office e&m - established), 796 times for 415 patients. In total Rajeev Yelamanchili billed 1,223 services in 16 codes, and Medicare paid $155K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-12-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 796 | 415 | $103.07 | $82K |
| 99204 Office E&M - New | Office | 90 | 90 | $129.76 | $12K |
| 95811 Sleep Study | Office | 63 | 55 | $587.80 | $37K |
| 94060 Pulmonary Function Testing | Office | 51 | 50 | $29.24 | $1,491 |
| 94726 Pulmonary Function Testing | Office | 51 | 50 | $43.68 | $2,228 |
| 94729 Pulmonary Function Testing | Office | 49 | 48 | $46.56 | $2,282 |
| 94618 Pulmonary Function Testing | Office | 46 | 45 | $28.04 | $1,290 |
| 94660 Treatment - Miscellaneous | Office | 27 | 22 | $49.58 | $1,339 |
| 95810 Sleep Study | Office | 26 | 25 | $538.37 | $14K |
By year: 2022 $163K for 1,612 services; 2023 $149K for 1,342 services; 2024 $155K for 1,223 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rajeev Yelamanchili prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 555 prescriptions and refills. In total Rajeev Yelamanchili wrote 2,544 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 555 | 986 | 211 | $38K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 202 | 357 | 61 | $221K |
| Prednisone Generic | 182 | 235 | 73 | $903 |
| Breyna Budesonide/Formoterol Fumarate | 114 | 232 | 47 | $44K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 113 | 197 | 40 | $38K |
| Incruse Ellipta Umeclidinium Bromide | 97 | 172 | 29 | $56K |
| Spiriva Respimat Tiotropium Bromide | 76 | 145 | 29 | $73K |
| Ventolin Hfa Albuterol Sulfate | 66 | 86 | 24 | $6,031 |
| Symbicort Budesonide/Formoterol Fumarate | 62 | 82 | 25 | $17K |
| Combivent Respimat Ipratropium/Albuterol Sulfate | 59 | 100 | 22 | $50K |
| Fluticasone Propionate Generic | 45 | 86 | 18 | $547 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 45 | 84 | 16 | $52K |
| Zolpidem Tartrate Generic | 39 | 43 | 13 | $392 |
| Tezspire Tezepelumab-Ekko | 37 | 44 | Under 11 | $182K |
| Roflumilast Generic | 35 | 49 | Under 11 | $2,099 |
Brand drugs: 1,450 claims; generic drugs: 1,094 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rajeev Yelamanchili $843 ($843 in general payments such as food, travel and fees) from 14 companies. The largest payer was GlaxoSmithKline, LLC. with $259.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 12 | $259 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $96.15 |
| Verona Pharma, Inc. VRNA | 3 | $65.88 |
| Philips North America LLC PHG | 4 | $62.18 |
| Insmed, Inc. INSM | 3 | $60.81 |
| Viatris Specialty LLC | 3 | $59.18 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $47.15 |
| Harmony Biosciences LLC HRMY | 1 | $46.33 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $31.88 |
| Baxter Healthcare BAX | 1 | $30.79 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.